Unlocking the Potential: Algae Products Projected to Reach $9.1 Billion by 2032 with Impressive 4.8% CAGR Sales Growth

The Market for Algae Products Continues to Grow Rising Healthcare Expenses and Increased Consumer Awareness Drive Demand Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) — Algae Products Market By Product (Hydrocolloids, Carotenoids & Pigments, Antioxidants, Lipids, Proteins), By Form (Powder, Liquid Algae Products), By Application (Food & Beverages, Cosmetics & … The market for algae products…

Read More

Attention Shareholders: Unisys Corporation (NYSE: UIS) Faces Class Action Lawsuit – What You Need to Know!

Did you lose money on investments in Unisys Corporation? Let’s talk about it! Calling all Unisys Corporation shareholders! Are you one of the unfortunate investors who lost money on investments in Unisys Corporation (NYSE: UIS)? If so, you may be entitled to compensation. Don’t suffer in silence – take action now by contacting Peter Allocco…

Read More

Breaking News: Lanier Biotherapeutics Receives U.S. Patent for IL-25 Binding Molecules – A Major Milestone in the World of Biotechnology!

Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Monoclonal Antibodies BOGART, Georgia, Nov. 14, 2022 (GLOBE NEWSWIRE) — Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, Type 2 inflammatory diseases, and oncology, today announced that the United States Patent and Trademark Office has issued U.S. Patent…

Read More

Longeveron Inc. Delivers Corporate Update and Reveals Third Quarter 2022 Financial Results: A Look into the Future of Biotechnology

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results Achieving Clinical and Regulatory Milestones Longeveron Inc. has achieved key clinical and regulatory milestones across its clinical pipeline. One notable accomplishment is the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease. This milestone marks a significant step forward in the…

Read More

Palisade Bio Crushes Q3 Earnings and Spills the Tea on Business Growth: A Must-Read Recap!

Welcome to the World of Palisade Bio! Financial Results and Business Update Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) Hey there, fellow health enthusiasts! Have you heard the latest news from Palisade Bio, Inc.? This innovative clinical stage biopharmaceutical company, traded as Nasdaq: PALI, is making waves in the world of gastrointestinal (GI) therapies. In…

Read More